Auris Medical Holding AG Company Profile (NASDAQ:EARS)

Analyst Ratings

Consensus Ratings for Auris Medical Holding AG (NASDAQ:EARS) (?)
Ratings Breakdown: 3 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $10.33 (164.96% upside)

Analysts' Ratings History for Auris Medical Holding AG (NASDAQ:EARS)
Show:
DateFirmActionRatingPrice TargetActions
6/15/2016Leerink SwannReiterated RatingBuy$12.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/10/2016Jefferies GroupReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/1/2015Needham & Company LLCReiterated RatingBuy$11.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/2/2014JMP SecuritiesInitiated CoverageOutperform$12.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/27/2014 forward)

Earnings

Earnings History for Auris Medical Holding AG (NASDAQ:EARS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/17/2016        
5/11/2016Q116($0.23)($0.27)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/14/2016Q415($0.28)($0.16)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/12/2015Q315($0.28)($0.15)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/19/2015Q215($0.23)($0.35)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/28/2015Q115($0.22)($0.29)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/19/2015Q4($0.23)($0.17)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
12/3/2014Q3($0.24)($0.14)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
9/15/2014($0.34)($0.27)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Auris Medical Holding AG (NASDAQ:EARS)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20163($0.29)($0.22)($0.25)
Q2 20163($0.33)($0.25)($0.28)
Q3 20163($0.38)($0.26)($0.31)
Q4 20163($0.44)($0.22)($0.32)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Auris Medical Holding AG (NASDAQ:EARS)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Auris Medical Holding AG (NASDAQ:EARS)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Latest Headlines for Auris Medical Holding AG (NASDAQ:EARS)
DateHeadline
07/21/16 09:12 PMAuris Medical Holding AG (NASDAQ:EARS) Stock Volatility Hits A Notable High - CML News
07/21/16 03:52 PMHercules Capital Provides $20MM Credit Facility to Auris Medical
07/20/16 04:57 PMDiscover Financial Services (NYSE:DFS) Earnings and Loans Rise: Auris Medical Holding AG (NASDAQ:EARS ... - KC Register
07/20/16 07:23 AMAuris Medical Holding AG (EARS) Current Analyst Ratings - Fiscal Standard
07/20/16 07:23 AMAuris Medical Secures Loan Facility of Up To $20 Million - GlobeNewswire (press release)
07/19/16 09:00 PMAuris Medical Holding (EARS) Enters $20M Loan Facility
07/19/16 03:54 PM4:54 pm Auris Medical entered into a loan facility agreement for up to $20 mln in financing -
07/19/16 03:49 PMAuris Medical Secures Loan Facility of Up To $20 Million
07/19/16 09:50 AMAuris Medical Holding's (EARS) Keyzilen Granted FDA Fast Track Designation in AP Tinnitus
07/19/16 09:50 AMFDA Grants Auris Medical Fast Track Designation for Keyzilen in Acute Peripheral Tinnitus
07/18/16 02:07 PMAuris Medical Gets FDA's Fast Track Designation For Keyzilen In Acute Peripheral Tinnitus -
07/18/16 08:49 AMAuris Medical Holding's (EARS) Keyzilen Granted FDA Fast Track Designation in AP Tinnitus - StreetInsider.com
07/14/16 03:23 PMDon't Miss: Himax Technologies (NASDAQ:HIMX), Auris Medical Holding AG (NASDAQ:EARS), Blue Capital ... - KC Register
07/14/16 03:23 PMAuris Medical Holding AG (NASDAQ:EARS) Short Interest Decreased By 2.11% - Press Telegraph
07/13/16 07:40 AMBroker Outlook For Auris Medical Holding AG (EARS) - Fiscal Standard
07/09/16 07:13 AMAuris Medical to Present at Cantor Fitzgerald's 2nd Annual Healthcare Conference on Tuesday, July 12 - P&T Community
07/08/16 03:46 PMAuris Medical to Present at Cantor Fitzgerald's 2nd Annual Healthcare Conference on Tuesday, July 12 - Stockhouse
07/08/16 07:59 AMAuris Medical to Present at Cantor Fitzgerald's 2nd Annual Healthcare Conference on Tuesday, July 12 - PharmiWeb.com (press release)
07/08/16 07:31 AMAuris Medical to Present at Cantor Fitzgerald's 2nd Annual Healthcare Conference on Tuesday, July 12 - [at noodls] - ZUG, Switzerland, July 8, 2016 (GLOBE NEWSWIRE) -- Auris Medical Holding AG (NASDAQ:EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology, ...
07/05/16 03:39 PMAuris Medical Holding AG (NASDAQ:EARS) Short Interest Decreased By 2.11% - Engelwood Daily
07/01/16 08:49 PMCould Auris Medical Holding AG See a Reversal After This Very Weak Session? - Press Telegraph
06/30/16 07:56 AMBig Movers: Auris Medical Holding AG (NASDAQ:EARS), Abraxas Petroleum Corp. (NASDAQ:AXAS), Pfizer Inc. (NYSE ... - KC Register
06/28/16 08:48 PMCould Auris Medical Holding AG Change Direction After Today's Huge Increase? - Engelwood Daily
06/28/16 03:42 PMAuris Medical Holding (EARS) Announces Completion of Keyzilen Phase 3 TACTT3 Enrollment - StreetInsider.com
06/28/16 07:31 AMAuris Medical Completes Enrollment of Phase 3 TACTT3 Trial with Keyzilen in Acute and Post-Acute Inner Ear Tinnitus - [at noodls] - Top-line results from TACTT3 trial expected in the fourth quarter Data to complement results from TACTT2 trial that are expected in August ZUG, Switzerland, June 28, 2016 (GLOBE NEWSWIRE) -- Auris Medical ...
06/27/16 03:43 PMAuris Medical Holding AG (EARS) Updated Price Targets - FTSE News
06/22/16 08:27 AMBiotech Losers: Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC), Auris Medical Holding AG (NASDAQ:EARS), Infinity ... - KC Register
06/20/16 09:31 AMAuris (EARS) Begins Phase III Study for Sudden Deafness -
06/18/16 08:17 AMAuris Medical Holding (EARS) Begins AM-111 Phase 3 as Sudden Deafness Treatment - StreetInsider.com
06/17/16 08:10 AMAuris Medical Holding (EARS) Begins AM-111 Phase 3 as Sudden Deafness Treatment
06/17/16 07:08 AMAuris Medical Initiates ASSENT Phase 3 Trial of AM-111 for Treatment of Sudden Deafness - [GlobeNewswire] - ZUG, Switzerland -- Auris Medical Holding AG (NASDAQ:EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology, today announced it ...
06/16/16 08:05 AMBiggest Moving Stocks Today – BCOM, PULM, AXDX, HMNY, EARS, CLRB, AKAO
06/16/16 07:39 AMAuris Medical to Present at the JMP Securities Life Sciences Conference on Wednesday, June 22 - [at noodls] - ZUG, Switzerland, June 16, 2016 (GLOBE NEWSWIRE) -- Auris Medical Holding AG (NASDAQ:EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology, ...
06/16/16 07:25 AMAuris Medical (EARS) Jumps: Stock Adds 15.2% in Session -
06/14/16 06:49 AMAuris Medical Hosts Key Opinion Leader Event Focused on Phase 3 Program for Acute Inner Ear Tinnitus - [at noodls] - Company introduces Keyzilen as brand name for AM-101 Keyzilen has potential to be first-ever approved therapy for tinnitus Live webcast of event begins today at 8 am EDT ZUG, Switzerland, June 14, 2016 ...
06/10/16 03:50 PMTrend Of Rating Given To Auris Medical Holding AG (NASDAQ:EARS) - Investor Newswire
06/07/16 09:24 PMAuris Medical to Host Key Opinion Leader Event Focused on Acute Inner Ear Tinnitus and AM-101's Phase 3 Program ... - Nasdaq
06/07/16 03:51 PMAuris Medical to Host Key Opinion Leader Event Focused on Acute Inner Ear Tinnitus and AM-101's Phase 3 Program ... - GlobeNewswire (press release)
06/07/16 09:40 AMAuris Medical to Host Key Opinion Leader Event Focused on Acute Inner Ear Tinnitus and AM-101s Phase 3 Program ... - EconoTimes
06/07/16 07:28 AMAuris Medical to Host Key Opinion Leader Event Focused on Acute Inner Ear Tinnitus and AM-101's Phase 3 Program on June 14 in New York City - [at noodls] - AM-101 has potential to be first-ever approved therapy for tinnitus Top-line results from first of two Phase 3 trials expected in August ZUG, Switzerland, June 7, 2016 (GLOBE NEWSWIRE) -- Auris Medical ...
06/06/16 01:33 PMAuris Medical Holding AG :EARS-US: Earnings Analysis: Q1, 2016 By the Numbers : June 6, 2016 -
06/05/16 03:41 PMAfter Last Week What Do Analysts Think Of Auris Medical Holding AG (EARS) - Share Trading News
06/02/16 08:22 AMAuris Medical to Present at the Jefferies 2016 Healthcare Conference on Thursday, June 9 - PharmiWeb.com (press release) - Auris Medical to Present at the Jefferies 2016 Healthcare Conference on Thursday, June 9PharmiWeb.com (press release)ZUG, Switzerland, June 2, 2016 (GLOBE NEWSWIRE) -- Auris Medical Holding AG (NASDAQ:EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology, today announced that ...and more »
06/02/16 07:15 AMAuris Medical to Present at the Jefferies 2016 Healthcare Conference on Thursday, June 9 - [at noodls] - ZUG, Switzerland, June 2, 2016 (GLOBE NEWSWIRE) -- Auris Medical Holding AG (NASDAQ:EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology, ...
06/01/16 03:56 PMBuy, Sell Or Hold Rating For Auris Medical Holding AG (EARS)? - Share Trading News - Buy, Sell Or Hold Rating For Auris Medical Holding AG (EARS)?Share Trading NewsAuris Medical Holding AG is a holding and clinical-stage biopharmaceutical company focused on the development of products for the treatment of inner ear disorders. Its advanced product candidate, AM-101, is in Phase III clinical development for acute ...
05/11/16 05:51 AMAuris reports 1Q loss -
05/04/16 07:40 AMAuris Medical to Announce First Quarter 2016 Financial Results and Host Conference Call on Wednesday, May 11, 2016 - [at noodls] - ZUG, Switzerland, May 4, 2016 (GLOBE NEWSWIRE) -- Auris Medical Holding AG (NASDAQ:EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology, ...
04/05/16 01:37 PMEdited Transcript of EARS earnings conference call or presentation 14-Mar-16 12:00pm GMT -
04/05/16 06:17 AMAuris Medical to Present at the 15th Annual Needham Healthcare Conference on Tuesday, April 12 - [at noodls] - ZUG, Switzerland, April 05, 2016 (GLOBE NEWSWIRE) -- Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in ...
03/30/16 05:49 AMAuris Medical Completes Enrollment of TACTT2 Phase 3 Trial of AM-101 in Acute Inner Ear Tinnitus - [at noodls] - Basel, Switzerland, March 30, 2016 (GLOBE NEWSWIRE) -- Auris Medical Holding AG (NASDAQ:EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in ...

Social

About Auris Medical Holding AG

Auris Medical Holding AG logoAuris Medical Holding AG is a holding and clinical-stage biopharmaceutical company focused on the development of products for the treatment of inner ear disorders. Its advanced product candidate, AM-101, is in Phase III clinical development for acute inner ear tinnitus under a special protocol assessment (SPA) from the United States Food and Drug Administration. Its second product candidate, AM-111, is being developed for the treatment of acute sensorineural hearing loss (ASNHL). It intends to conduct over two pivotal Phase III trials in the treatment of idiopathic sudden SNHL (ISSNHL), titled Acute Inner Ear Hearing Loss (HEALOS) and Acute Sudden Sensorineural Hearing Loss Treatment (ASSENT). AM-111 received orphan drug designation for the treatment of ASNHL from the United States Food and Drug Administration, and the European Union agency. It intends to conduct a Phase II trial in the treatment of surgery-induced hearing loss (REACH).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: EARS
  • CUSIP:
Key Metrics:
  • Previous Close: $3.90
  • 50 Day Moving Average: $3.88
  • 200 Day Moving Average: $3.98
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $133.88M
  • Beta: 0.6
  • Current Year EPS Consensus Estimate: $-0.94 EPS
  • Next Year EPS Consensus Estimate: $-0.85 EPS
Additional Links:
Auris Medical Holding AG (NASDAQ:EARS) Chart for Wednesday, July, 27, 2016